Aventis' Lovenox Label Revises Pharmacokinetics, Dosage Information
This article was originally published in The Pink Sheet Daily
Executive Summary
Updated Lovenox label provides additional information for obese and low-weight patients, and those with renal impairment. Labeling recommends dose adjustment for patients with severe renal impairment who have increased exposure to enoxaparin.